# Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026 - Egetis Therapeutics
Canonical URL: https://biopharmsignal.com/news/EGTX/egetis-to-present-healthcare-resource-drivers-and-cost-in-mct8-deficiency-at-isp-c2a98b15
Ticker: EGTX
Company: Egetis
Source: Egetis
Published: 2026-07-09 00:01 EST
Original Source URL: https://www.egetis.com/mfn_news/
## Summary

Stockholm, Sweden, May 19, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced its participation in the annual conference of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2026, taking place May 17 to 20, 2026, in Philadelphia, PA, USA. ISPOR is a leading global conference for health economics […]

## Article Body
Stockholm, Sweden, May 19, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced its participation in the annual conference of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2026, taking place May 17 to 20, 2026, in Philadelphia, PA, USA.

ISPOR is a leading global conference for health economics and outcomes research, offering an important forum for scientific exchange among researchers, healthcare stakeholders, and decision makers.

Anny Bedard, President North America at Egetis, said: “Participation in the ISPOR conference represents an important opportunity for Egetis to engage with the global health economics and outcomes research community. We look forward to sharing our work, advancing meaningful dialogue, and contributing evidence that helps shape a deeper understanding of the real-world impact of MCT8 deficiency."

Egetis will present a scientific poster titled Healthcare resource drivers and cost among MCT8 deficiency patients in the United States highlighting the Company’s continued commitment to advancing awareness about MCT8 deficiency, including the burden of disease.

Poster Session: Poster Session 5 Poster Code and Link: EE487 Poster Session Date/Time: Wednesday, May 20, 9:00 AM – 11:30 AM EDT Discussion Period: 9:00 AM – 10:00 AM EDT
## Recent Company News
- 2026-07-09 15:46 EST — [Exercise of options under employee stock option program and notification of insider trading - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/exercise-of-options-under-employee-stock-option-program-and-notification-of-insi-e6812443) — Source: Egetis
- 2026-07-09 00:02 EST — [Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026 - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/egetis-therapeutics-to-participate-in-leading-international-medical-conferences--5e606850) — Source: Egetis
- 2026-07-09 00:01 EST — [Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026 - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/egetis-to-present-healthcare-resource-drivers-and-cost-in-mct8-deficiency-at-isp-c2a98b15) — Source: Egetis
- 2026-07-09 00:01 EST — [Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/egetis-therapeutics-announces-national-re-airing-of-behind-the-mystery-episode-o-f519aa28) — Source: Egetis
- 2026-05-29 00:00 EST — [Change in the number of shares and votes in Egetis Therapeutics - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/change-in-the-number-of-shares-and-votes-in-egetis-therapeutics-egetis-therapeut-efcee0d2) — Source: Egetis
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)